Exciting Advances in ROS1-Positive NSCLC Treatment to Be Shared at AACR 2026

Nuvation Bio's Pivotal Research on IBTROZI

Nuvation Bio Inc. is poised to make significant contributions to the oncology community by presenting their latest findings on IBTROZI® (taletrectinib) at the upcoming American Association for Cancer Research (AACR) Annual Meeting in 2026. These findings will highlight the effectiveness and safety of this innovative therapy for patients suffering from advanced ROS1-positive non-small cell lung cancer (NSCLC).

Scheduled to take place from April 17 to 22, 2026, in San Diego, the presentations will showcase several enlightening data updates stemming from the TRUST-I and TRUST-II clinical studies. These studies focus on TKI-naïve (tyrosine kinase inhibitor-naïve) and TKI-pretreated patients afflicted with ROS1+ NSCLC. This fresh data brings nearly an additional year of follow-up since the FDA's approval of IBTROZI in June 2025.

Key Findings to Be Presented

The results underscore the remarkable durability of IBTROZI in TKI-naïve patients, with the median Duration of Response (DOR) reportedly exceeding four years, enhancing the expectations for patient outcomes. David Hung, M.D., the Founder, President, and CEO of Nuvation Bio, expressed his excitement over this extended follow-up, emphasizing the sustained clinical benefits for patients alongside a manageable safety profile.

For the oral presentation, Dr. Lyudmila Bazhenova will present the findings on the DOR in TKI-naïve patients during a session dedicated to advances in precision oncology. The poster presentations will be delivered by Geoffrey Liu, M.Sc., M.D., focusing on the safety and efficacy of taletrectinib in TKI-pretreated patients. Additional insights will come from Dr. Hitisha Patel, who will shed light on the differentiated profile of taletrectinib in ROS1 fusion models.

Why This Research Matters

Lung cancer, specifically NSCLC, accounts for a significant number of cancer diagnoses worldwide, with over one million reported cases annually. Among these, approximately two percent are attributed to ROS1-positive tumors, which pose particular challenges in treatment. This disease often metastasizes to the brain, complicating the clinical landscape further.

The findings that will be detailed at AACR 2026 are crucial as they may provide new avenues for medical professionals in treating patients diagnosed with ROS1-positive NSCLC. As the understanding of this condition evolves, therapies like IBTROZI stand at the forefront, challenging existing treatment paradigms and raising new hopes for affected patients.

About Nuvation Bio

Nuvation Bio is a dedicated global oncology company that designs and develops more efficient cancer therapies aimed at solving pressing challenges in cancer treatment. Known for its innovative approach, the company has a range of drugs in its pipeline, including taletrectinib (IBTROZI), a next-generation ROS1 inhibitor, among others.

In conclusion, the upcoming AACR Annual Meeting promises to be a transformative platform for disseminating important findings related to ROS1-positive NSCLC treatments. The continued development and research into therapies like IBTROZI by Nuvation Bio highlight advancements in patient care and the relentless pursuit of better therapeutic outcomes.